While the price surge in shares of Selecta Biosciences (NASDAQ:SELB) receded slightly on October 26 with the stock rising only 10.6% to close at $3.13 per share, strong insider buying and a rare pediatric disease designation may maintain the upward […]
As you may have read recently or noticed, shares of BioXcel Therapeutics (NASDAQ:BTAI) recorded a 627% gain in seven months after SanaCurrents’ December 20, 2019 report that forecast positive outcomes for two, separate phase III trials for BioXcel’s drug BXCL501. The 627% […]
Last Friday, the FDA granted emergency use authorization (EUA) to Gilead Sciences, Inc. (NASDAQ:GILD) remdesivir to treat patients hospitalized with COVID19. The EUA approval came within days after Gilead and NIH scientists released clinical study results demonstrating the statistical significance […]
SanaCurrents is closing its position in Antibe this week, due to strong share performance and lack of clarity on key data. In the past year, Antibe Therapeutics (ATE:CN) (OTCQB: ATBPF) ($0.48, $145.5m market cap) delivered solid progress on the phase IIb efficacy […]
This content is for members only
This content is for members only
One of the strongest performing biopharmaceutical stocks this year is Evolus (EOLS). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then its […]
SanaCurrents is increasing the frequency of its sentiment reports to subscribers to 3 per month. We anticipate there will be a significant number of important catalysts this year for SanaCurrents companies and we did not want you to miss out on any. […]